However, there is not yet a clinically relevant method to increase intracellular ceramide levels, as a potential anticancer strategy for melanoma with dysregulated ceramide metabolism, although exogenous ceramide analogues, as well as anti-S1P approaches, have been tested in several preclinical studies 152. The gene discussed is MBTPS1; the disease is melanoma.